Every material Form 8-K GALECTIN THERAPEUTICS INC has filed with the SEC since May 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Galectin Therapeutics reported its June 30, 2026 quarterly results, with a net loss applicable to common stockholders of $9.2 million, or $0.14 per share, up from $7.6 million, or $0.12 per share, a year earlier. The increase was mainly due to a $3.2 million charge for the change in fair value of derivative liabilities, and the company also reported that a $105.8 million debt conversion into common stock strengthened its balance sheet and that it reached FDA alignment on its planned Phase 3 trial.
Q2 2026 net loss applicable to common stockholders was $9.2 million, or $0.14 per share, versus $7.6 million, or $0.12 per share, in Q2 2025
Chairman Richard Uihlein's conversion of about $105.8 million in debt and accrued interest into 34,376,167 common shares took effect July 31, 2026
Cash and cash equivalents were $13.2 million at June 30, 2026, with $10 million remaining under the chairman's line of credit; the company expects cash to fund planned operations through June 2027
The company expects to submit the registrational Phase 3 protocol for belapectin in the third quarter of 2026
Galectin Therapeutics said its Type C meeting with the FDA produced agreement on the primary endpoint and regulatory path for a potential full approval of belapectin in patients with MASH cirrhosis and portal hypertension. The company plans to file the Phase 3 protocol in the third quarter of 2026 and is exploring strategic and financial partnerships to support development.
FDA agreed to a composite liver outcome primary endpoint that includes prevention of large esophageal varices (>5 mm)
FDA accepted the company's proposed blinded central review process for endoscopic assessments, based on the NAVIGATE trial approach
Company plans a single 2 mg dose in the Phase 3 trial and expects a trial size generally comparable to NAVIGATE
Phase 3 protocol submission anticipated in the third quarter of 2026; company is actively pursuing partners
Galectin Therapeutics reported a first-quarter 2026 net loss applicable to common stockholders of $5.1 million, or $0.08 per share, down from $9.6 million, or $0.15 per share, a year earlier, mainly because research and development expenses fell to $2.2 million from $6.5 million. The company had $14.1 million of cash at March 31, 2026, plus $10 million left on a credit line from its chairman, and said this covers planned operations through May 2027, but its stockholders' deficit widened to $132.0 million.
Net loss applicable to common stockholders was $5.1 million ($0.08 per share) for the quarter ended March 31, 2026, versus $9.6 million ($0.15 per share) a year earlier.
Research and development expenses were $2.2 million, down from $6.5 million, which the company attributed mainly to timing of NAVIGATE trial expenditures.
Cash and cash equivalents were $14.1 million at March 31, 2026, with $10 million remaining under a line of credit from the chairman of the board.
Data from the NAVIGATE trial will be presented at EASL in May 2026, and an in-person Type-C meeting with the FDA is planned for the second quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every GALECTIN THERAPEUTICS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →